Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Drug Discovery & Development › Bristol Myers' Idhifa Fails to Meet Phase III Survival Endpoint in Refractory AML

Bristol Myers' Idhifa Fails to Meet Phase III Survival Endpoint in Refractory AML

Aug 25, 2020
|
staff reporter

NEW YORK – Bristol Myers Squibb announced on Tuesday that its acute myeloid leukemia drug enasidenib (Idhifa) combined with best supportive care failed to significantly extend overall survival compared to conventional regimens in relapsed and refractory patients with an IDH2 mutation.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
23
Featured Webinar

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar
25
Featured Webinar

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

Mar
30
Featured Webinar

Circulating Tumor Cells in Breast Cancer: Understanding a Validated Diagnostic Tool for Precision Medicine

Sponsored by
Menarini Silicon Biosystems

This webinar will provide an overview of the current state of circulating tumor cell (CTC) enumeration for clinical use in metastatic breast cancer.

What's Popular?

In Cancer

  1. Tempus, Texas Oncology Subsidiary Form Data-Focused Precision Oncology Partnership

  2. Natera Launches Tumor Genomic Profiling Assay, Expects Reproductive Health to Break Even This Year

    Premium

  3. Guardant360 CDx Receives CE Mark for Tumor Mutational Profiling and Tagrisso CDx Use

  4. Genetic Testing Challenges in Oncology: Forged Genetic Test Report Leads to Incorrect Management

  5. Strata Oncology, Pfizer Partner to Explore New Biomarker Indications for FDA-Approved Drugs

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.